KRAS and pancreatic neoplasm: We demonstrated that cfDNA KRAS mutations were detectable at the time of diagnosis in the plasma of 20% of pancreatic cancer cases at PDAC hotspot codons (12, 13 and 61); a sensitivity which is more consistent with some studies (between 27 to 36%) [14, 16, 20, 25] than others (between 47 to 81%) [15, 17–19].